Lisanti Capital Growth LLC Invests $1.44 Million in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Lisanti Capital Growth LLC bought a new stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to its most recent filing with the SEC. The firm bought 23,285 shares of the medical equipment provider’s stock, valued at approximately $1,444,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. MeadowBrook Investment Advisors LLC acquired a new position in shares of Lantheus during the fourth quarter worth $189,000. M&T Bank Corp purchased a new position in Lantheus in the 4th quarter valued at about $320,000. First Horizon Advisors Inc. grew its stake in shares of Lantheus by 103.9% during the fourth quarter. First Horizon Advisors Inc. now owns 932 shares of the medical equipment provider’s stock valued at $58,000 after acquiring an additional 475 shares in the last quarter. Retirement Systems of Alabama increased its position in shares of Lantheus by 0.4% during the fourth quarter. Retirement Systems of Alabama now owns 85,779 shares of the medical equipment provider’s stock worth $5,318,000 after acquiring an additional 336 shares during the last quarter. Finally, Sector Gamma AS increased its position in shares of Lantheus by 2.7% during the fourth quarter. Sector Gamma AS now owns 52,316 shares of the medical equipment provider’s stock worth $3,244,000 after acquiring an additional 1,354 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Friday. B. Riley lifted their price target on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. Truist Financial increased their price objective on shares of Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research note on Friday. Mizuho boosted their target price on shares of Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a research report on Friday, February 23rd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $99.17.

Lantheus Stock Performance

Shares of NASDAQ LNTH traded up $0.50 during midday trading on Tuesday, hitting $76.01. The company’s stock had a trading volume of 1,014,686 shares, compared to its average volume of 1,080,942. The firm has a market cap of $5.27 billion, a P/E ratio of 11.53 and a beta of 0.52. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $100.85. The firm’s fifty day moving average price is $62.82 and its 200-day moving average price is $62.75. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.55 and a current ratio of 4.84.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. The company had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. On average, sell-side analysts forecast that Lantheus Holdings, Inc. will post 5.96 EPS for the current fiscal year.

Insider Buying and Selling at Lantheus

In other news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The stock was acquired at an average price of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now owns 116,773,394 shares of the company’s stock, valued at $110,934,724.30. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. In other Lantheus news, Director Mary Anne Heino sold 93,863 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total transaction of $6,130,192.53. Following the completion of the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction dated Wednesday, March 6th. The shares were acquired at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the acquisition, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Over the last three months, insiders have sold 94,545 shares of company stock worth $6,169,936. 2.10% of the stock is owned by insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.